Actively Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Led by Janssen Research & Development, LLC · Updated on 2026-05-08
40
Participants Needed
5
Research Sites
67 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (Dose expansion) of study.
CONDITIONS
Official Title
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed adenocarcinoma of the prostate; adenocarcinomas with neuroendocrine features allowed
- Metastatic castration-resistant prostate cancer metastatic to bone or lymph nodes without clear visceral metastasis
- Prior orchiectomy or medical castration and ongoing androgen deprivation therapy with GnRH analog
- Prostate-specific antigen (PSA) of at least 2 ng/mL at screening
- Measurable or evaluable disease
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
You will not qualify if you...
- Toxicity from prior anticancer therapy not recovered to grade 1 or baseline (except alopecia, grade 2 neuropathy, vitiligo)
- Known allergies or intolerance to pasritamig or JNJ-86974680 components
- Active infection requiring systemic antibiotics within 7 days before first dose (prophylaxis allowed)
- Leptomeningeal disease or brain metastases except stable, treated brain metastases off corticosteroids for at least 2 weeks
- Serious medical conditions or issues that impair treatment tolerance, informed consent understanding, or protocol assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
Actively Recruiting
2
Columbia University Medical Center
New York, New York, United States, 10032
Actively Recruiting
3
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
Actively Recruiting
4
The Christie NHS Foundation Trust Christie Hospital
Manchester, United Kingdom, M20 4BX
Actively Recruiting
5
Royal Marsden Hospital
Sutton, United Kingdom, SM2 5PT
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here